Comprehensive guide to Wharton's jelly stem cells (WJ-MSCs). Collection methods, unique advantages over other stem cell sources, therapeutic applications, and clinical evidence.
Wharton's jelly is the gelatinous connective tissue that insulates and protects blood vessels within the umbilical cord. It is extraordinarily rich in mesenchymal stem cells — yields of 2–4 million MSCs per cm of umbilical cord are achievable, versus 10,000–100,000 cells per ml of bone marrow aspirate. WJ-MSCs express high levels of pluripotency-associated transcription factors (Oct-4, Sox-2, Nanog) compared to adult-source MSCs, reflecting their neonatal origin and superior regenerative potency.
Unlike bone marrow or adipose MSCs from an adult donor, WJ-MSCs have very low expression of MHC class II antigens and do not trigger allogeneic immune rejection in published cross-matching studies. This means patients can receive WJ-MSCs from healthy screened donors without HLA matching or immunosuppression — a critical safety and practical advantage over bone marrow transplantation. StemCell Longevita uses only GMP-certified WJ-MSCs from rigorously screened donors, with 97%+ viability guarantee at point of delivery.
Umbilical cords are collected from healthy, consenting mothers after planned caesarean deliveries. Donors undergo extensive screening: infectious disease panel (HIV, hepatitis B/C, CMV, syphilis), genetic screening, and maternal health review. Cord processing follows EU GMP standards. Cells are expanded in certified bioreactor systems, cryopreserved in GMP-grade cryoprotectant, and released only after passing sterility, endotoxin, karyotype, and viability testing.
Related articles: Cord Blood vs. Bone Marrow Stem Cells: Which Is Better for Treatment? | Mesenchymal Stem Cells (MSCs): What Every Patient Should Know | Types of Stem Cells Explained (2026 Update)
Related treatments: Anti-Aging Stem Cell Therapy | Autoimmune Disease Stem Cell Therapy | Diabetes Stem Cell Therapy